



Improving Mobility and Quality
of Life by Augmenting and
Restoring Muscle Function

Quadriceps Weakness Exacerbates Knee Osteoarthritis


US \$15B in Treatment Expenses (Rx, Braces, Injections)

US \$12B in Indirect Expenses (Lost Productivity)

- 1 Continued knee damage
- 2 Increased joint pain
- 3 Missed time at work
- 4 Decreased quality of life
- 5 Earlier knee replacement



Physical Therapy Effectiveness Impacted by Access, Compliance



KneeStim™

Dynamically
strengthening muscle
during everyday activity

Bringing physical
therapy to the patient

Differentiation Through Intelligence and Adaptation

- **KneeStim™ Functions**
 - Dynamic, real-time muscle stimulation
 - Short (<5 min) personalization period
 - Stim + muscle usage = improved strength gains
- **KneeStim™ Advantages**
 - 50% faster recovery from quad atrophy, inhibition¹
 - Syncs with normal movement and PT activity
 - Greater convenience - light, mobile, forgettable
 - Remote therapy and measurement



Applying Adaptive AI to Rehab Technology for Improved Efficacy, Outcomes, and Convenience




Standard NMES

Passive, stationary therapy with uncomfortable stimulation pulses for 15 minutes



Knee Braces

Physically unloads the joint; can be bulky and difficult to wear under clothing



KneeStim

Light, low-profile, comfortable device that seamlessly integrates strengthening into normal activity

Determined Management Team & Scientific Advisors

Team



Josh Rabinowitz, Co-Founder & CEO

Market strategy, execution, business development, and strategic partnerships



Herbie Kirn, Co-Founder & CSO

Start-up veteran; prior exit w/ \$12M raised; 55+ patents in control systems & embedded design



Kyle Kircher, Chief Commercial Officer

30 years in physical medicine sales leadership, channel partner development, and rapid commercialization



Proxima CRO

Regulatory and quality partner

Scientific Advisors



Dr. J. Michael Bennett

Orthopedic surgeon & sports medicine specialist



Dr. Anthony ("AJ") Johnson

Orthopedic Sports Medicine Director



Dr. Shou-Hsiu ("James") Chang

Director, UTHealth NeuroRecovery Research Center



DesignPlex Biomedical

Design for manufacturing and contract manufacturing partner



Recent Commercial Traction & Development De-Risking

Regulatory Approval & Reimbursement

- FDA Class II 510(k) in Process
- Applicable HCPCS & CPT reimbursement coding and coverage determined

Intellectual Property

- Four US, Four EU utility patents granted
- IP claims applicable to all joints and conditions

Market Interest

- 65% of interviewed MDs interested or highly interested in Rx'ing KneeStim
- 55% of knee patients interested or highly interested in KneeStim; 80% willing to pay out-of-pocket

External Investment



techstars



USAMRAA
UNITED STATES ARMY
Medical Research
Acquisition Activity

Awards



Rx+
HEALTHCARE
INNOVATION
CHALLENGE



WINNER
IoT/WT
INNOVATION
WORLD CUP®

powered by **AiQ.**

Engaged Facilities



Texas College of
Osteopathic Medicine



JPS Health Network
Fort Worth, Texas




crr sion
clinique romande de réadaptation


Large Addressable Markets for KneeStim™ Within U.S.

B2B2C - Selling to surgical centers and physical therapy clinics through DME/HME suppliers

- 1 \$ 11B Total Market**
15M seeking knee treatment in U.S.
- 2 \$ 4.5B Servicable Market**
6.3M with knee OA aged 45-64; still employed and seeking to reduce time lost from work
- 3 \$ 1.0B Obtainable Market**
1.3M target customers within Texas



\$100M+ Revenue Within Serviceable Addressable Market



Assumptions / Economics

- 1 Engaged MD = 30-45 Rx's / Mo
- 40%+ Margin for DMEs
- COGS, OpEx % reduce with scaling
- Uptake will follow data, consistent reimbursement
- v2 KneeStim available DTC; higher price point



Summary / Targeted Outcomes

Accelerate patient rehab following injuries and surgery

Improve patient function with minimal effort or cost

Expand platform technology to address other MSKIs



WINNER

**IoT/WT
INNOVATION
WORLD CUP®**

powered by **AiQ.**



Josh Rabinowitz, Co-Founder & CEO
248/408-1503 | josh@articulatelabs.com